-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluocinolone Acetonide Sr in Posterior Uveitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluocinolone Acetonide Sr in Posterior Uveitis report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using...
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. The following are some of the key highlights of the Uveitis clinical trials analysis: North America led with more than 30% of the clinical trials conducted as of July 2023. In 2023, Novartis AG has conducted the highest number of uveitis clinical trials. The US had...
-
Company Profile
EyePoint Pharmaceuticals Inc – Company Profile
EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant...
Add to Basket -
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinal Vein Occlusion is a blockage in one of the veins returning blood flow from the retina. Its predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion pipeline market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Net Present Value Model: Vorolanib
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vorolanib Drug Details Vorolanib is under...
-
Product Insights
Net Present Value Model: Dexycu
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Dexycu Drug Details Dexamethasone (Dexycu/ IBI-10090)...
-
Product Insights
Net Present Value Model: Yutiq
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Yutiq Drug Details Fluocinolone acetonide (Iluvien,...
-
Track & Monitor
Innovation in Pharmaceuticals: Glycoside hydrolase-based drug compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – vorolanib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry vorolanib Drug Details Vorolanib is under development for the treatment of wet age-related macular...